HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating and announces Price Target of $9.
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating and announces Price Target of $9.